A possible relation of BDNF and GDNF to neuropsychiatric disorders

Yoko Hibi, Atsumi Nitta, Toshitaka Nabeshima, Kiyofumi Yamada

Research output: Contribution to journalShort survey

4 Citations (Scopus)

Abstract

Structural abnormalities are demonstrated in various neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and even major depression. On the other hand, recent studies have demonstrated the structural and functional modifications in the adult brain that are associated with synaptic plasticity and neurogenesis. Accordingly, regulation of synaptic plasticity and neurogenesis may lead to the development of novel treatments for neuropsychiatric disorders. Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) have important roles not only in neuronal survival and differentiation, but also in the formation and maintenance of neural circuits and synapse plasticity. Accumulating evidence suggests that these neurotrophic factors may be applied to the treatment of neuropsychiatric disorders. In addition, compounds that increase the expression of BDNF and/or GDNF in the brain should have potential therapeutic values. We have demonstrated that systemic administration of dipeptide Leu-Ile increases BDNF and GDNF production in the brain, and has a protective role in methamphetamine and morphine dependence. In this review, we discuss the potential role of BDNF, GDNF and their inducers in the treatment for neuropsychiatric disorders.

Original languageEnglish
Pages (from-to)85-89
Number of pages5
JournalJapanese Journal of Neuropsychopharmacology
Volume29
Issue number2
Publication statusPublished - 01-04-2009
Externally publishedYes

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Brain-Derived Neurotrophic Factor
Neuronal Plasticity
Neurogenesis
Brain
Morphine Dependence
Methamphetamine
Dipeptides
Nerve Growth Factors
Synapses
Parkinson Disease
Alzheimer Disease
Maintenance
Depression

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Hibi, Yoko ; Nitta, Atsumi ; Nabeshima, Toshitaka ; Yamada, Kiyofumi. / A possible relation of BDNF and GDNF to neuropsychiatric disorders. In: Japanese Journal of Neuropsychopharmacology. 2009 ; Vol. 29, No. 2. pp. 85-89.
@article{efe5f2a9612b4767806befb301711938,
title = "A possible relation of BDNF and GDNF to neuropsychiatric disorders",
abstract = "Structural abnormalities are demonstrated in various neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and even major depression. On the other hand, recent studies have demonstrated the structural and functional modifications in the adult brain that are associated with synaptic plasticity and neurogenesis. Accordingly, regulation of synaptic plasticity and neurogenesis may lead to the development of novel treatments for neuropsychiatric disorders. Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) have important roles not only in neuronal survival and differentiation, but also in the formation and maintenance of neural circuits and synapse plasticity. Accumulating evidence suggests that these neurotrophic factors may be applied to the treatment of neuropsychiatric disorders. In addition, compounds that increase the expression of BDNF and/or GDNF in the brain should have potential therapeutic values. We have demonstrated that systemic administration of dipeptide Leu-Ile increases BDNF and GDNF production in the brain, and has a protective role in methamphetamine and morphine dependence. In this review, we discuss the potential role of BDNF, GDNF and their inducers in the treatment for neuropsychiatric disorders.",
author = "Yoko Hibi and Atsumi Nitta and Toshitaka Nabeshima and Kiyofumi Yamada",
year = "2009",
month = "4",
day = "1",
language = "English",
volume = "29",
pages = "85--89",
journal = "Japanese Journal of Psychopharmacology",
issn = "1343-4144",
publisher = "Japanese Society of Neuropsychopharmacology",
number = "2",

}

A possible relation of BDNF and GDNF to neuropsychiatric disorders. / Hibi, Yoko; Nitta, Atsumi; Nabeshima, Toshitaka; Yamada, Kiyofumi.

In: Japanese Journal of Neuropsychopharmacology, Vol. 29, No. 2, 01.04.2009, p. 85-89.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - A possible relation of BDNF and GDNF to neuropsychiatric disorders

AU - Hibi, Yoko

AU - Nitta, Atsumi

AU - Nabeshima, Toshitaka

AU - Yamada, Kiyofumi

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Structural abnormalities are demonstrated in various neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and even major depression. On the other hand, recent studies have demonstrated the structural and functional modifications in the adult brain that are associated with synaptic plasticity and neurogenesis. Accordingly, regulation of synaptic plasticity and neurogenesis may lead to the development of novel treatments for neuropsychiatric disorders. Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) have important roles not only in neuronal survival and differentiation, but also in the formation and maintenance of neural circuits and synapse plasticity. Accumulating evidence suggests that these neurotrophic factors may be applied to the treatment of neuropsychiatric disorders. In addition, compounds that increase the expression of BDNF and/or GDNF in the brain should have potential therapeutic values. We have demonstrated that systemic administration of dipeptide Leu-Ile increases BDNF and GDNF production in the brain, and has a protective role in methamphetamine and morphine dependence. In this review, we discuss the potential role of BDNF, GDNF and their inducers in the treatment for neuropsychiatric disorders.

AB - Structural abnormalities are demonstrated in various neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and even major depression. On the other hand, recent studies have demonstrated the structural and functional modifications in the adult brain that are associated with synaptic plasticity and neurogenesis. Accordingly, regulation of synaptic plasticity and neurogenesis may lead to the development of novel treatments for neuropsychiatric disorders. Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) have important roles not only in neuronal survival and differentiation, but also in the formation and maintenance of neural circuits and synapse plasticity. Accumulating evidence suggests that these neurotrophic factors may be applied to the treatment of neuropsychiatric disorders. In addition, compounds that increase the expression of BDNF and/or GDNF in the brain should have potential therapeutic values. We have demonstrated that systemic administration of dipeptide Leu-Ile increases BDNF and GDNF production in the brain, and has a protective role in methamphetamine and morphine dependence. In this review, we discuss the potential role of BDNF, GDNF and their inducers in the treatment for neuropsychiatric disorders.

UR - http://www.scopus.com/inward/record.url?scp=67651024700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651024700&partnerID=8YFLogxK

M3 - Short survey

VL - 29

SP - 85

EP - 89

JO - Japanese Journal of Psychopharmacology

JF - Japanese Journal of Psychopharmacology

SN - 1343-4144

IS - 2

ER -